EUVIMEDEUVIMED entdecken
Crossref

Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis

Shang Li iD, Liangliang Ma, Xinxin Li, Yuhan Jiang, Zhongwen Luo, Fucheng Yin iD, Yonglei Zhang, Yifan Chen iD, Siyuan Wan, Han Zhou, Lingyi Kong iD, Xiaobing Wang iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c00949 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Shang Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Bioactive Natural Product Research, Department of Natural Medicinal Chemistry…. Hauptthemen laut MEDLINE: Necroptosis, Protein Kinases, Proteolysis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: ?333 Project? of Jiangsu Province, Double First Class University Plan, Basic Research Program of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mixed lineage kinase domain-like pseudokinase (MLKL) initiates necroptosis and could serve as a therapeutic target related to a series of human diseases. Proteolysis-targeting chimeras (PROTACs) are useful tools for degrading pathological proteins and blocking disease processes. Using computer-aided modeling and molecular dynamics simulations, we developed a series of covalent MLKL PROTACs by linking and optimizing a theophylline derivative that covalently targets MLKL. Via structure-activity relationship studies, MP-11 was identified as a potent MLKL PROTAC degrader. Furthermore, MP-11 showed lower toxicity than the original MLKL ligand, exhibiting nanomolar-scale antinecroptotic activity on human cell lines. Xenograft model studies showed that MP-11 effectively degraded MLKL in vivo. Importantly, our study demonstrates that the covalent binding strategy is an effective approach for designing MLKL-targeting PROTACs, serving as a model for developing PROTACs to treat future necroptosis-related human diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NecroptosisProtein KinasesProteolysisAnimalsHumansMiceAntineoplastic AgentsCell Line, TumorDrug DiscoveryLigandsMice, NudeMolecular Dynamics SimulationStructure-Activity RelationshipXenograft Model Antitumor AssaysOligopeptides

Substanzen

Antineoplastic AgentsLigandsProtein KinasesMLKL protein, humanMP 11Oligopeptides

Autor:innen und Institutionen

  • State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Bioactive Natural Product Research, Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China.

ORCID-Profile: Shang Li, Fucheng Yin, Yifan Chen, Lingyi Kong, Xiaobing Wang

Förderung

  • ?333 Project? of Jiangsu Province
  • Double First Class University Plan
  • Basic Research Program of Jiangsu Province
  • Six Talent Peaks Project in Jiangsu Province
  • Higher Education Discipline Innovation Project
  • Jiangsu Scientific Research and Practice Innovation Project

Zitieren

APA

Li, S., Ma, L., Li, X., Jiang, Y., Luo, Z., Yin, F., Zhang, Y., Chen, Y., Wan, S., Zhou, H., Kong, L., & Wang, X. (2024). Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00949

Vancouver

Li S, Ma L, Li X, Jiang Y, Luo Z, Yin F, et al. Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00949

BibTeX
@article{Li2024,
  author = {Li, Shang and Ma, Liangliang and Li, Xinxin and Jiang, Yuhan and Luo, Zhongwen and Yin, Fucheng and Zhang, Yonglei and Chen, Yifan and Wan, Siyuan and Zhou, Han and Kong, Lingyi and Wang, Xiaobing},
  title = {Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c00949}
}
Kostenlos starten →